Data Year:

For its 2025 fiscal year, Sarepta Therapeutics, Inc., listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2025
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
Ian M. Estepan
President, Chief Operating Officer
Total Compensation $4,444,393 View details Pay Rank By Title In Biotechnology industry #32 View more
Louise Rodino-Klapac Ph.D.
President, Research and Development and Technical Operations
Total Compensation $4,456,270 View details Pay Rank By Title In Biotechnology industry #2 View more
Douglas S. Ingram
Chief Executive Officer
Total Compensation $7,840,666 View details Pay Rank By Title In Biotechnology industry #158 View more
Dallan Murray
Former Executive Vice President, Chief Customer Officer
Total Compensation $2,742,790 View details Pay Rank By Title In Biotechnology industry #96 View more
Cristin L. Rothfuss
Executive Vice President, General Counsel
Total Compensation $4,233,623 View details Pay Rank By Title In Biotechnology industry #57 View more
Ryan H. Wong
Executive Vice President, Chief Financial Officer
Total Compensation $3,211,867 View details Pay Rank By Title In Biotechnology industry #136 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at Sarepta Therapeutics, Inc. as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. Sarepta Therapeutics, Inc. income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. Sarepta Therapeutics, Inc. annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Ian M. Estepan
President, Chief Operating Officer
Total Cash $1,000,529 Equity $3,426,845 Other $17,019 $4,444,393
Louise Rodino-Klapac Ph.D.
President, Research and Development and Technical Operations
Total Cash $1,012,505 Equity $3,426,845 Other $16,920 $4,456,270
Douglas S. Ingram
Chief Executive Officer
Total Cash $1,820,425 Equity $6,000,005 Other $20,236 $7,840,666
Dallan Murray
Former Executive Vice President, Chief Customer Officer
Total Cash $373,095 Equity $1,647,913 Other $721,782 $2,742,790
Cristin L. Rothfuss
Executive Vice President, General Counsel
Total Cash $789,308 Equity $3,426,845 Other $17,470 $4,233,623
Ryan H. Wong
Executive Vice President, Chief Financial Officer
Total Cash $617,615 Equity $2,577,968 Other $16,284 $3,211,867
For its 2025 fiscal year, Sarepta Therapeutics, Inc., listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Douglas S. Ingram CEO Pay $7,840,666 Median Employee Pay $308,335 CEO Pay Ratio 25:1
For its 2025 fiscal year, Sarepta Therapeutics, Inc., listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Claude Nicaise, M.D. Total Cash $554,466
Deirdre Connelly Total Cash $558,153
Hans Wigzell, M.D., Ph.D. Total Cash $562,466
Kathryn J. Boor, Ph. D. Total Cash $552,466
M. Kathleen Behrens, Ph.D. Total Cash $603,923
Michael Chambers Total Cash $544,466
Richard J. Barry Total Cash $577,279
Stephen L. Mayo, Ph.D. Total Cash $556,966
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.